Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2030

Conditions
Pulmonary TB
Interventions
DRUG

Extra 600mg of Rifampicin

Intervention group participants will receive standard treatment (RHZE), plus an optimised regimen consisting of RIfampicin at 20 mg/kg (additional 600mg rifampicin in each weight band) during a shortened treatment period of 16 weeks.

DRUG

Placebo

The standard treatment regimen for DS-TB (rifampicin at 10 mg/kg and isoniazid for 6 months, plus pyrazinamide and ethambutol for the first 2 months; 2RHZE/4RH), with additional placebo for the first 4 months (16 weeks).

All Listed Sponsors
collaborator

St George's, University of London

OTHER

collaborator

McMaster University

OTHER

lead

Hamilton Health Sciences Corporation

OTHER